BACKGROUND: Diagnostic performance of high-sensitivity cardiac troponin T (hs-cTnT) varies depending on presenting symptoms in patients with suspected acute coronary syndrome (ACS).
cTnT measurements. Higher hs-cTnT cutoffs at baseline and absolute changes after 6 h help to identify non-STEMI (ST segment elevation myocardial infarction) in this population.
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Implementation of more sensitive and high-sensitivity (hs) 2 cardiac troponin assays at the 99th percentile cutoff has improved early rule-out of acute myocardial infarction (AMI) due to substantially higher sensitivities and negative predictive values (1) (2) (3) . Despite the high analytical sensitivity of hs-cardiac troponin T (cTnT) assays, clinical specificities still may be low because more patients with positive cardiac troponin results are being identified in the absence of an acute coronary syndrome (ACS), and assay specificity depends on the cutoff concentration. Major tasks in an emergency department (ED) are not only to rule out AMI accurately but also to discriminate non-ST segment elevation myocardial infarction (STEMI) from non-ACS-related conditions, particularly among those who present with an increased cardiac troponin result. Performance measures of baseline and serial cardiac troponin measurements for the diagnosis of AMI using sensitive and hs-cardiac troponin assays range from excellent, with areas under the curve (AUCs) between 0.92 and 0.96 (1, 4 -6 ) , to moderate, with AUCs as low as 0.73 (7 ) , even with the use of the same hs-cTnT assay (1, 5, 7 ) , indicating a potential influence of the study cohort.
Due to the higher pretest probability of ACS in the presence of typical chest pain (8 ) , the performance of hs assays may be overrated because the loss of clinical specificity of hs-cTnT is not critical in highly selected patients with typical chest pain. Reference trials suggesting the implementation of hs-cardiac troponin assays (1, 2 ) and reinforcing the recommendation to use earlier diagnostic algorithms (9, 10 ) included only patients with chest pain as the leading symptom. In clinical practice, however, testing for AMI is not restricted to these subgroups but is used in many patients with dyspnea and atypical chest pain.
Performance of hs-cardiac troponin assays and early diagnostic algorithms may not be applicable in EDs, in which patients present with a much broader spectrum of symptoms. Therefore, the aim of the present study was to investigate the role of presenting symptoms on diagnostic performance and predictive power of hs-cTnT in patients with suspected ACS.
Methods

STUDY POPULATION
Of 3327 consecutive presentations to our ED during a 6-month period, we identified all patients with suspected ACS as indicated by the physician on duty or the emergency physician. Patients presented with a broad spectrum of acute symptoms, including typical chest pain, dyspnea, and atypical manifestations including isolated back pain; jaw, arm, or shoulder pain; gastric discomfort; diaphoresis; collapse; or syncope.
Typical chest pain (angina) was defined according to European Society of Cardiology guidelines as intermittent or persistent retrosternal pressure or heaviness radiating to the left arm, neck, or jaw lasting for at least 20 min (11 ) . AMI was diagnosed according to the criteria of the third version of the universal MI definition (12 ) . Patients with STEMI were excluded. Diagnosis of non-STEMI required the detection of a rising and/or falling pattern with a change of 20% or more and a minimal absolute change of Ն5 ng/L, regardless of whether cTnT was increased at admission. However, only patients with at least 1 value above the 99th percentile were included. AMI was not further differentiated into type 1 (spontaneous) or type 2 MI (oxygen dysbalance), because the diagnostic performance of troponin testing does not seem to be affected by the AMI subtype (13 ) . In case the diagnostic criteria for AMI were not met, patients underwent careful clinical examination to clarify other causes of myocardial damage. ACS and non-ACS diagnoses were retrospectively readjudicated by 2 cardiologists who had full access to laboratory, echocardiography, multislice computed tomography, cardiac MRI, and coronary angiography data.
Patients presenting with the leading symptom of dyspnea comprised a broad spectrum of possible conditions ranging from influenza and pneumonia to decompensated heart failure and pulmonary embolism.
LABORATORY MEASUREMENTS
Cardiac troponin was measured in serum on a COBAS E411 using the hs-cTnT assay (Roche Diagnostics), which is commercially available in Germany (not yet available in the US). The limit of blank and limit of detection have been determined to be 3 ng/L and 5 ng/L (3 ). The 10% CV was determined at 13 ng/L in 100 measurements in the authors' laboratory. The interassay CV was 8% at 10 ng/L and 2.5% at 100 ng/L. The intraassay CV was 5% at 10 ng/L and 1% at 100 ng/L. Reference intervals were established from a multicenter reference study and the 99th percentile value was determined at 14 ng/L (14 ) .
Along with admission values, several kinetic metrics were calculated from serial measurements, including ␦ given as percent change in either direction (rise or fall) of hs-cTnT from baseline, absolute concentration differences from baseline to 3 and 6 h, and peak hs-cTnT concentration within 6 h. A recent issue regarding lot-tolot variation of the hs-cTnT assay was considered (15 ) , but none of the affected lots was used in this study.
STATISTICAL ANALYSIS
Continuous variables were tested for normal distribution and were presented either as mean (SD) or as medians with 25th and 75th percentiles. Groups were compared using the 2 test for categorical variables and ANOVA for continuous variables. We determined optimal thresholds for relative and absolute changes from ROC curves on the basis of the continuously measured biomarker concentrations. To compare AUCs, the test of DeLong et al. was used (16 ) . ROC optimized cutoffs were calculated using the closest point to the upper left corner according to the method proposed by Zweig et al. (17 ) . We calculated performance measures, including sensitivities and specificities for baseline hs-cTnT and for absolute and relative concentration changes within 6 h. All performance measures were calculated separately for the entire population, for patients presenting with typical chest pain, dyspnea, and atypical symptoms like back pain, arm or shoulder pain, diaphoresis, collapse, or syncope. The SPSS 20.0 (IBM) and MedCalc 11.1 (MedCalc software) statistical software packages were used. All tests were 2-tailed and a P value of Ͻ0.05 was considered statistically significant.
Results
BASELINE CHARACTERISTICS
During a 6-month period, 3327 patients presenting to the ED were screened. A total of 721 patients with a condition suggestive of an ACS were included into the study, of whom 63 patients with STEMI or new left bundle branch block (LBBB) were excluded. Typical chest pain was the leading presenting syndrome in 241 (36.6%) patients, dyspnea in 142 (21.6%) of the patients, and atypical symptoms in 275 patients (41.8%, Table 1 .
DIAGNOSTIC IMPLICATIONS OF ADMISSION SYMPTOMS
A diagnosis of non-STEMI or UAP was more frequent among patients presenting with typical chest pain (42.7% and 40.7%) compared to dyspnea (7.0% and 3.5%, both P Ͻ 0.001) or atypical symptoms (12.0% and 9.5%, both P Ͻ 0.001), whereas non-ACS diagnoses were more common in patients with dyspnea (89.4%, P Ͻ 0.001) and atypical symptoms (75.6%, P Ͻ 0.001) compared to typical chest pain (16.6%). Diagnostic performance of hs-cTnT clearly differed in the 3 subgroups defined by the leading symptom on admission. Accordingly, the AUC of admission hs-cTnT values for the diagnosis of non-STEMI was highest in patients presenting with typical chest pain (AUC, 0.823), followed by those with dyspnea (AUC, 0.776) and atypical symptoms (AUC, 0.705, Fig. 2 ) (P ϭ 0.04).
Irrespective of the presenting symptom, absolute concentration changes within 6 h demonstrated a significantly better performance to diagnose non-STEMI (AUC, 0.873) than admission values (AUC, 0.728, P Ͻ 0.001) or relative changes within 6 h (AUC, 0.761, P Ͻ 0.001, Fig. 3) . However, the difference between the AUC curve derived from baseline values only and the curve derived with the addition of absolute concentration changes was small in patients presenting with typical chest pain (⌬AUC, 0.078, P ϭ 0.02) or acute dyspnea (⌬AUC, 0.050, P Ͼ 0.05). Nevertheless, the additional consideration of absolute changes resulted in significant increments of the diagnostic performance in patients with atypical symptoms (⌬AUC, 0.166, P ϭ 0.005). Clinical sensitivity of hs-cTnT baseline values and kinetic changes was highest in patients with typical chest pain, whereas specificity of admission values und abso- lute changes was highest in patients presenting with dyspnea ( Table 2) . Coronary angiography was performed more often and earlier in patients with typical chest pain (81.7%, 73.5% within 24 h) than in patients presenting with dyspnea (35.2%, 36.7% within 24 h, both P Ͻ 0.001) or atypical symptoms (28.4%, 49.4% within 24 h, both P Ͻ 0.001). In addition, percutaneous coronary intervention (PCI) was performed more often in patients with typical chest pain (57.1%; dyspnea, 22.4%, P Ͻ 0.001; atypical, 43.3%, P Ͻ 0.001). In-hospital management is described in Table 1 in the Data Supplement that accompanies the online version of this report at http://www. clinchem.org/content/vol61/issue5.
PROGNOSTIC IMPLICATIONS OF ADMISSION SYMPTOMS
Death or the combined endpoint death/AMI was observed in 8.3% and 9.1% of patients with typical chest pain, 17.6% and 18.3% of patients with dyspnea, and 10.9% and 12.0% of patients with atypical symptoms. Patients presenting with dyspnea had a higher risk of death and the combined endpoint compared to patients with typical chest pain [hazard ratio (HR), 95% CI, death, 2.36, 1.26 -4.43, P ϭ 0.008; death/AMI, 2.23, 1.21-4.11, P ϭ 0.01] (Table 3) . Likewise, the risk of 
CHARACTERISTICS OF PATIENTS PRESENTING WITH DYSPNEA
Patients presenting with dyspnea were older, had more severe kidney dysfunction, were more often diagnosed with non-ACS conditions, had worse outcome, and presented earlier compared to patients with typical chest pain ( Table 1 ). An ACS was diagnosed in only 10.5% of patients with dyspnea. In this group, hs-cTnT admission values were higher than in patients with non-ACS [median (95% CI) 106.1 (45.8 -752.0) ng/L vs 36.7 (23.3-65.6) ng/L, P Ͻ 0.001]. In contrast, NT-proBNP values were lower in ACS patients with dyspnea (see online Supplemental Table 2 ). hs-cTnT cutoffs for diagnosis of non-STEMI were higher in patients presenting with dyspnea for admission values (91.2 vs 14.1 ng/L, P Ͻ 0.001) and absolute changes within 6 h (31.7 vs 8.4 ng/L, P Ͻ 0.001; see online Supplemental Table 3 ). Acute dyspnea was associated with higher rates of death or death/AMI during 1-year follow-up, regardless of whether ACS or non-ACS was the underlying reason (see online Supplemental Fig. 2 ).
Discussion
The present study provides 3 important findings concerning the diagnostic workup of ACS patients. First, the quality of the presenting symptom strongly influences the performance of hs-cTnT for the diagnosis of non-STEMI. Second, acute dyspnea, which is a common leading presenting symptom of consecutive patients admitted for suspected ACS (21.6% in our study), was associated with impaired diagnostic performance of hs-cTnT and a higher risk for adverse outcome. Third, increased hs-cTnT values are associated with adverse outcome even in patients presenting with atypical symptoms.
The implementation of hs-cardiac troponin assays in clinical routine has facilitated rapid rule-out of non-STEMI in patients presenting with suspected ACS to the ED due to higher sensitivities and negative predictive values compared to conventional assays (1-3 ) . However, because of the low specificity of these assays, the correct identification of non-STEMI remains challenging (1, 7, 9 ) . Leading presenting symptoms are associated with different pretest probabilities for ACS and might therefore be helpful in the identification of AMI in patients with suspected ACS (8 ) . Patients admitted to the ED may present with a variety of symptoms, but typical chest pain and dyspnea remain the most important complaints in individuals that undergo troponin testing in the ED (18 ) . It appears that the diagnostic performance of cardiac troponin was excellent in studies with chest pain as the qualifying symptom (1, 2, 4, 10 ) whereas only a moderate accuracy has been reported in studies enrolling patients with a broader range of symptoms (7, 9 ) . ACS was common and the suspected diagnosis in 21.7% of all patients. This rate was higher than in general internal medicine ED. Although our ED is specialized in the workup of patients presenting with chest pain, a broad spectrum of conditions is treated including arrhythmias, hypertensive crisis, acute dyspnea, and acute heart failure, but not trauma. The prevalence of non-STEMI in our cohort was 20% and thus comparable with trials focusing on patients presenting with typical chest pain for which a diagnosis of non-STEMI was made in 17%-23% (1, 2, 4, 6, 10 ) . In our analysis, the presence of typical chest pain as the leading presenting symptom compensated for the decrease of clinical specificity that was related to the increase of analytical sensitivity using hs-cardiac troponin assays (19 ) . Accordingly, performance of hs-cTnT for diagnosis of non-STEMI was highest among those patients presenting with typical chest pain and lowest among those presenting with atypical symptoms, or dyspnea. This is additional evidence supporting the hypothesis that qualifying symptoms influence clinical specificities because rates of non-STEMI and non-ACS conditions differ largely between study cohorts. Accordingly, prevalence of hs-cTnT exceeding the 99th percentile was only 9%-15% in studies that restricted inclusion to chest pain (9 ) as opposed to 51.2% (7 ), 63% (20 ) , and 65.8% (21 ) reported in studies including patients with a broader range of symptoms. Conversely, rates of patients with increased cardiac troponin due to non-ACS conditions were considerably lower in studies enrolling exclusively patients with chest pain (1, 2, 5, 6 ) compared to studies with more comprehensive enrollment criteria (9, 20, 21, 22 ) . In confirmation of these findings, patients presenting with dyspnea had the highest hs-cTnT concentrations and were more often diagnosed with non-ACS conditions in our study. Accordingly, specificities of hs-cTnT admission values and absolute changes within 6 h were highest in this group. Dyspnea is particularly important because it is highly prevalent in ACS patients, with rates between 17% (23 ), 34.3% (24 ) , 45% (25 ) (in patients Ͼ75 years old), and 49.3% (26 ) . At 21.6%, the prevalence of dyspnea was rather at the lower end in our analysis. This might be explained by the focus of our ED on ACS patients, whereas reference studies included patients of general internal medicine EDs. Furthermore, dyspnea has been associated with a high risk of adverse outcome (26 ) . Accordingly, it was strongly associated with high-risk features, including high NT-proBNP concentrations and high GRACE scores, in our study. Not unexpectedly, dyspnea was associated with a 2.4-fold higher adjusted risk of death and a 2.2-fold higher adjusted risk of death/ AMI compared to typical chest pain. In keeping with these findings, numerous previous studies have provided incremental evidence that patients with atypical symptoms define a high-risk group because they are more likely to be older (26, 27 ) , female (24, 28 ) , hypertensive, diabetic, and to have a history of heart failure (24, 26 ) . The higher risk associated with atypical presentation compared to typical chest pain is substantiated by higher rates of in-hospital heart failure, cardiogenic shock, sustained ventricular tachycardia or ventricular fibrillation, atrial fibrillation or flutter, renal failure, or death (26 ) . Although the prevalence of non-STEMI was low in patients presenting with dyspnea (7.0% in our analysis), early diagnosis is paramount, especially in this group, because early allocation to invasive strategy has proved to be effective in reducing mortality and recurrent AMI in high-risk patients (29 ) . In support, we observed that patients with dyspnea received coronary angiography later than those with typical chest pain. Although AMI can ultimately be excluded in the majority of patients presenting with acute dyspnea, identification of non-STEMI and thus discrimination of a non-ACS condition from ACS among patients presenting with signs or symptoms of acute heart failure is important for the indication and timing of an invasive strategy to restitute normal myocardial perfusion. Guidelines for the management of acute heart failure recommend measurement of cardiac troponin with a class I level of evidence A to exclude underlying myocardial ischemia as the reason for acute deterioration (30 ) . However, identification of AMI in patients presenting with dyspnea is particularly challenging owing to the lower pretest probability, lower AUCs, and lower sensitivity, as our analysis revealed.
Selection of patients with a very high clinical pretest probability of an ACS may be desired for randomized pharmaceutical or interventional trials to ensure correct enrollment and avoid unnecessary interventions and overtreatment but does not reflect the real world. Presentation to an ED with acute dyspnea represents a clinical challenge, because a non-STEMI that manifests with symptoms of acutely decompensated heart failure is diagnosed in only 7%-10% of cases and is more difficult to diagnose and to treat. Identification of the underlying reason for acute dyspnea is paramount because acute dyspnea is associated with higher rates of death or death/ AMI during 1-year follow-up, regardless whether ACS or non-ACS was the exact underlying reason (26 ) . According to the findings in our study, it appears that considerably higher hs-cTnT cutoffs are required to diagnose a non-STEMI in patients presenting with dyspnea or atypical chest pain to overcome the lack of clinical specificity, and thus to discriminate a non-ACS-related condition from non-STEMI. In addition, serial measurements using absolute concentration changes rather than relative concentration changes improve the diagnostic performance of hs-cTnT, more importantly among patients presenting with atypical symptoms or acute dyspnea.
LIMITATIONS
A limitation of this analysis might be the low rate of ACS in the screened ED population, although we enrolled patients presenting to a dedicated cardiology ED. However, the proportion of patients presenting with ACS was comparable to other studies that focused on the diagnostic and prognostic performance of cardiac troponin (1, 2, 4, 6, 10 ) . Furthermore, because cardiac troponin testing is mainly applied in ACS patients, inclusion of patients with other suspected diagnoses would have impaired the validity of our results. Another issue is the inclusion of patients presenting to a dedicated "Chest Pain Unit." It might therefore be problematic to apply the results in general internal medicine EDs. However, patients presented with a broad range of symptoms including dyspnea and atypical symptoms and therefore represent a real-life population. Furthermore, reference trials that focused on the diagnostic performance of cardiac troponins mainly included patients presenting with chest pain. Nevertheless, we observed comparable rates of ACS and non-STEMI in our population. We also did not use sex-specific cutoffs; some reference range studies have shown significant differences between men and women.
